Joo Hyuk Sohn
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
Goetz M, Toi M, Huober J, Sohn J, Trédan O, Park I, Campone M, Chen S, Manso L, Paluch-Shimon S, Freedman O, O'Shaughnessy J, Pivot X, Tolaney S, Hurvitz S, Llombart-Cussac A, Andre V, Saha A, van Hal G, Shahir A, Iwata H, Johnston S. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3. Ann Oncol 2024
08.05.2024Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
08.05.2024Ann Oncol 2024
Goetz Matthew P, Toi Masakazu, Huober Jens, Sohn Joo Hyuk, Trédan Olivier, Park In Hae, Campone Mario, Chen S-C, Manso L M, Paluch-Shimon Shani, Freedman Orit C, O'Shaughnessy Joyce, Pivot X, Tolaney Sara M, Hurvitz Sara A, Llombart-Cussac Antonio, Andre Valerie A M, Saha A, van Hal G, Shahir Ashwin, Iwata H, Johnston Stephen R D
In Reply
Rugo H, Huober J, García-Sáenz J, Masuda N, Sohn J, Andre V, Barriga S, Cox J, Goetz M. In Reply. Oncologist 2021; 26:e1286-e1287.
19.04.2021In Reply
19.04.2021Oncologist 2021; 26:e1286-e1287
Rugo Hope S, Huober Jens, García-Sáenz José A, Masuda Norikazu, Sohn Joo Hyuk, Andre Valerie A M, Barriga Susana, Cox Joanne, Goetz Matthew
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
Rugo H, Huober J, García-Sáenz J, Masuda N, Sohn J, Andre V, Barriga S, Cox J, Goetz M. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist 2021; 26:e522.
01.03.2021Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
01.03.2021Oncologist 2021; 26:e522
Rugo Hope S, Huober Jens, García-Sáenz José A, Masuda Norikazu, Sohn Joo Hyuk, Andre Valerie A M, Barriga Susana, Cox Joanne, Goetz Matthew
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
Rugo H, Huober J, García-Sáenz J, Masuda N, Sohn J, Andre V, Barriga S, Cox J, Goetz M. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist 2020; 26:e53-e65.
09.10.2020Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
09.10.2020Oncologist 2020; 26:e53-e65
Rugo Hope S, Huober Jens, García-Sáenz José A, Masuda Norikazu, Sohn Joo Hyuk, Andre Valerie A M, Barriga Susana, Cox Joanne, Goetz Matthew